First Survival Win for CDK4/6 Inhibitors in High-Risk Early-Breast Cancer

(MedPage Today) — BERLIN — For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall survival (OS) in high-risk early breast cancer, data reported here showed. Patients who received…